MACROD2 and breast carcinoma: It is unclear how MACROD2 expression may be associated with clinical outcome in relation to drug responsiveness, exemplified by a primary breast cancer study that showed that MACROD2 overexpression was associated with worse survival, probably due to resistance to anti-estrogen receptor-alpha therapy (tamoxifen) [14].